Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
28716404
DOI
10.1016/j.gie.2017.07.009
PII: S0016-5107(17)32090-4
Knihovny.cz E-resources
- MeSH
- Anastomosis, Surgical instrumentation methods MeSH
- Bariatric Surgery methods MeSH
- Diabetes Mellitus, Type 2 complications drug therapy metabolism MeSH
- Adult MeSH
- Endoscopy, Gastrointestinal methods MeSH
- Glycated Hemoglobin metabolism MeSH
- Hypoglycemic Agents therapeutic use MeSH
- Jejunum surgery MeSH
- Blood Glucose metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Magnets * MeSH
- Obesity complications metabolism surgery MeSH
- Pilot Projects MeSH
- Prediabetic State complications metabolism MeSH
- Prospective Studies MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Glycated Hemoglobin A MeSH
- hemoglobin A1c protein, human MeSH Browser
- Hypoglycemic Agents MeSH
- Blood Glucose MeSH
BACKGROUND AND AIMS: Most patients with type 2 diabetes mellitus have obesity. Studies show that bariatric surgery is superior to medical treatment for remission of type 2 diabetes mellitus. Nevertheless, very few patients undergo surgery, and a less-invasive endoscopic alternative is desirable. METHODS: This was a single-arm first-in-human pilot study designed to evaluate the technical feasibility, safety, and clinical performance of the incisionless magnetic anastomosis system (IMAS) to create a partial jejunal diversion (PJD). Ten patients with obesity and type 2 diabetes mellitus, prediabetes, or no diabetes were enrolled. A PJD to the ileum was attempted in all patients under general anesthesia. The IMAS was delivered through the working channel of a colonoscope, with laparoscopic supervision. The patients were not required to participate in an intensive lifestyle/diet management program. Endoscopic visualization of the anastomosis was obtained at 2, 6, and 12 months. Patient weight, glycemic profile, and metabolic panels were acquired at 0.5, 1, 2, 3, 6, 9, and 12 months. RESULTS: A PJD was created in all patients with no device-related serious adverse events. The anastomosis remained widely patent in all patients at 1 year. Average total weight loss was 14.6% (40.2% excess weight loss at 12 months). A significant reduction in glycated hemoglobin level was observed in all diabetic (1.9%) and prediabetic (1.0%) patients, while reducing or eliminating the use of diabetes medications. CONCLUSIONS: Permanent anastomosis for PJD was created in all patients with the IMAS. This resulted in improvement in measures of hyperglycemia and progressive weight loss. (Clinical trial registration number: NCT02839512.).
Brigham and Women's Hospital Boston Massachusetts USA
Emerson Hospital Concord Massachusetts USA; Massachusetts General Hospital Boston Massachusetts USA
References provided by Crossref.org
ClinicalTrials.gov
NCT02839512
